

MATERIALS LICENSE

Amendment No. 25

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Woodland Medical Group
2. 22341 West Eight Mile Road
Detroit, MI 48219

In accordance with application dated
January 28, 1985
3. License number 21-13255-01 is amended in
its entirety to read as follows:

4. Expiration date May 31, 1990

5. Docket or
Reference No. 030-02149

6. Byproduct, source, and/or
special nuclear material

7. Chemical and/or physical
form

8. Maximum amount that licensee
may possess at any one time
under this license

A. Any byproduct material
listed in Groups I
and II of Schedule A,
Section 35.100 of
10 CFR 35

A. Any radiopharmaceutical
listed in Groups I
and II of Schedule A,
Section 35.100 of
10 CFR 35

A. As necessary for
uses authorized
in Subitem 9.A

B. Any byproduct material
listed in Group III of
Schedule A, Section
35.100 of 10 CFR 35

B. Any form listed in
Group III of Schedule A,
Section 35.100 of
10 CFR 35

B. 2 curies
of each byproduct
material authorized
in Subitem 6.B

C. Any byproduct material
listed in Group IV of
Schedule A, Section
35.100 of 10 CFR 35

C. Any radiopharmaceutical
listed in Group IV of
Schedule A, Section
35.100 of 10 CFR 35

C. As necessary for
uses authorized
in Subitem 9.C

D. Any byproduct material
listed in Section
31.11(a) of 10 CFR 31

D. Prepackaged kits

D. 3 millicuries
of each byproduct
material authorized
in Subitem 6.D

E. Xenon-133

E. Gas or gas in solution
that is the subject
of an active (i.e., not
withdrawn or terminated)
"New Drug Application"
(NDA) approved by FDA or
an active (i.e., not
withdrawn, terminated
or on "clinical hold")
"Notice of Claimed
Investigational Exemption
for a New Drug" (IND)
that has been accepted
by FDA

E. 200 millicuries

8505030192 850423
REG3 LIC30
21-13255-01 PDR

COPY

A/51
2
me30
4/2/85

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

21-13255-01

Docket or Reference number

030-02149

Amendment No. 25

6. Byproduct, source,
and/or special nuclear
material

7. Chemical and/or
physical form

8. Maximum amount that
licensee may possess
at any one time
under this license

F. Americium 241

F. Sealed source Amersham/
Searle Model No. AMC.24

F. 12 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. In vitro studies

E. Blood flow studies. Pulmonary function studies.

F. To be used in Searle Analytic Anatomical Marker Model SS-10244.

10. Licensed material shall be used only at the licensee's facilities located at 22341 West Eight Mile Road Detroit, Michigan and 41935 West Twelve Mile Road, Novi, Michigan.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material shall be used by Harold Daitch, M.D., Richard Small, M.D. or Seymour H. Mirkes, M.D.

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License number

21-13255-01

Docket or Reference number

030-02149

Amendment No. 25

14. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated January 28, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.



For the U.S. Nuclear Regulatory Commission

Date April 23, 1985

Original Signed
By George M. McCann
Materials Licensing Section, Region III
COPY